Related Experiment Video

Updated: Oct 26, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.7K

AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma

Keitaro Fukuda1,2, Ken Okamura1, Rebecca L Riding1

  • 1Department of Dermatology, University of Massachusetts Medical School, Worcester, MA.

The Journal of Experimental Medicine
|July 29, 2021
PubMed

Insights

Targeting absent in melanoma 2 (AIM2) in dendritic cells (DCs) improves melanoma immunotherapy. AIM2 deficiency enhances anti-tumor immunity by promoting T cell recruitment and reducing regulatory T cells, offering a new therapeutic strategy.

Area of Science:

  • Immunology
  • Oncology
  • Dendritic Cell Biology

Background:

  • Cytosolic DNA activates STING and absent in melanoma 2 (AIM2) pathways.
  • STING agonists improve immunotherapy, but AIM2's role in melanoma is unclear.
  • Dendritic cell (DC) expression of AIM2 in human melanoma correlates with poor prognosis.

Purpose of the Study:

  • To investigate the role of AIM2 in the melanoma microenvironment.
  • To evaluate the therapeutic potential of targeting AIM2 in DCs for melanoma treatment.

Main Methods:

  • Assessed AIM2 expression in human melanoma DCs.
  • Utilized AIM2-deficient DCs for vaccination in mouse models.
  • Administered adoptive T cell therapy and anti-PD-1 immunotherapy.
  • Analyzed immune cell infiltration and cytokine profiles.
  • Employed AIM2 siRNA in mouse and human DCs.

Main Results:

  • AIM2 expression in DCs correlates with poor melanoma prognosis and exerts immunosuppressive effects.
  • Vaccination with AIM2-deficient DCs enhances efficacy of T cell therapy and anti-PD-1 immunotherapy for cold tumors.
  • AIM2 deficiency promotes STING-dependent type I IFN secretion, CXCL10 production, and CD8+ T cell recruitment.
  • Reduced AIM2-dependent IL-1β and IL-18 processing further enhances treatment response by limiting regulatory T cell infiltration.
  • AIM2 targeting in DCs (in vivo and in vitro) boosts anti-tumor immune responses.

Conclusions:

  • AIM2 acts as an immunosuppressive factor in the melanoma microenvironment.
  • Targeting AIM2 in tumor-infiltrating dendritic cells represents a promising therapeutic strategy for melanoma.
  • AIM2 inhibition can convert 'cold' tumors into 'hot' tumors responsive to immunotherapy.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.1K
Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation05:33

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation

Published on: September 6, 2024

1.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
778
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K